Nonalcoholic steatohepatitis (NASH) Pipeline Analysis

“Non-alcoholic steatohepataitis (NASH) Pipeline Analysis” gives comprehensive

insights on the various drugs being developed for the treatment of NASH. The report covers
all the drugs that are in various phases of development (Discovery, Preclinical & Clinical).
The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small
molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based
therapeutics, but excludes symptom relief drugs, generic combinations and supplemental
drugs. The report also covers some of the hot targets in research for NASH treatments and
NASH related biomarkers.

This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual

researchers, Investors, Medical technology companies, Service providers and other
associated stake holders to identify and analyze the available licensing/collaborative
commercial opportunities in the Non-alcoholic steatohepataitis (NASH) drugs market. The
report also provides strategic insights on some of the molecules that are yet to be launched
in the next few years. NASH is associated with fatty liver, hepatic inflammation, hepatocyte
injury and fibrogenesis and may worsen into fibrosis or cirrhosis, liver failure and rarely into
liver cancer. Currently, there are no approved drugs for NASH by U.S. Food and Drug
Administration (FDA) and there a high unmet clinical need. NASH, if untreated can progress
to liver-destroying cirrhosis and potentially cancer. Majority of the NASH pipeline drugs are
from specialized small to mid-pharmaceutical & biotech companies. As some of the
candidates are nearing key R&D milestones, there is a huge competition among large
pharmaceutical and biotech companies to acquire these assets. Promethera’s acquisition of
Baliopharm for NASH antibody program, Gilead’s acquisition of Phenex FXR program &
Boehringer’s acquisition of NASH clinical asset from Pharmaxis supports this trend.
Diagnosis of NASH still requires histological confirmation and there is a great demand for
specific non-invasive diagnosis for distinguishing NASH from other liver diseases. Therefore,
there is a need to develop better diagnostic and therapeutic strategies for patients with
NASH. Some of the key sections covered in the report are given below:

 Epidemiology
o In this section, epidemiology of NASH is reviewed to understand potential
significance and impact of the disease.
o Global & US prevalence rates.
 Hot Targets, Mechanisms & Therapies

IQ4I Research & Consultancy Pvt. Ltd. Page 1

Nonalcoholic steatohepatitis (NASH) Pipeline Analysis

o In this section, various NASH associated targets, mechanism and upcoming

therapies are discussed. The report has 206 preclinical molecules, covers novel
targets in early research for NASH along with disease progression biomarkers
associated with NASH (Inflammatory, apoptosis, fibrosis).
 Market analysis
o In market analysis section, global NASH drugs market is indicated along with the
estimated Peak sales ($) of leading clinical stage drugs forecasted from 2020-
2026.
o Forecasting model for NASH market.
o NASH market dynamics.
o NASH Market and estimated Peak sales of 11 clinical candidates (GR-MD-02 -
Gilead, GFT505 - Genfit, OCA - Intercpt, IVA 337 - Inventiva Pharma, Aramchol -
Galmed, Selonsertib - Gilead, Cenicriviroc - Allergan, IMM-124E - Immuron,
MGL 3196 - Madrigal, GS-0976 - Gilead, Emricasan – Conatus).
o NASH related deals analysis with financials (upfront, milestones and royalties).
o Funding scenario in NASH market.
 Pipeline Analysis
o Pipeline analysis was carried to get deeper insights on various treatment
modalities in discovery, preclinical & development section, pipelines from major
companies were identified and Potential targets were reported along with
Mechanism of action, Current development status & nature of molecule. Pipeline
analysis by developmental stage (Discovery to Clinical development).
o Pipeline analysis by modalities
 Monoclonal Antibodies pipeline analysis
 RNA-therapeutics pipeline analysis
 Recombinant protein pipeline analysis
o Pipeline analysis by leading players & Target analysis
o Drug analysis based on mechanism (Anti-Inflammatory, Anti-fibrotic and
Metabolic)
 Key Players Analysis
o The key player’s analysis section provides an in-depth understanding of various
companies working on Nonalcoholic steatohepatitis (NASH) and their Pipelines
with development phase as well as understanding partnering strategies such as
deals entered by the company
o Global key players overview

IQ4I Research & Consultancy Pvt. Ltd. Page 2

Nonalcoholic steatohepatitis (NASH) Pipeline Analysis

o Global key players Pipeline data (Discovery, Pre-clinical & Clinical development)
o A global key players deals (Collaborations, Licensing, Service agreements,
grants, funds).

IQ4I Research & Consultancy Pvt. Ltd. Page 3